OTC COMMAND (@OTCCOMMAND) header
OTC COMMAND (@OTCCOMMAND) profile picture

OTC Command ⚔️ OTC DD, charts, filings, catalysts & sentiment. No hype. No fluff. Smarter speculation. NFA.

Arizona, USA
Joined September 2017
Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)Photo by OTC COMMAND (@OTCCOMMAND)
$SONO breakdown 📊 ✅ Q4 beat: adj EPS $0.04 (a profit), revenue $344M +20% YoY ✅ $150M buyback, ~7% of the company ✅ Broke out of a 6-month $13-$18.40 box ⚠️ Now testing ~$20, the ceiling from 2024 & 2025 Close over $20 on volume = room to run. NFA
44
🤣🤣🤣
Nvidia CEO'su Jensen Huang yaptığın çipler ile farkında olmadan kendi mezarını kazmış :)) Yaptığı çiplerle yaratılan yapay zeka videosu... Atalarımız güzel demiş: ''Kırkından sonra azanı teneşir paklar.''
85
$VFF in at $2.93 📈 Q3 beat: EPS $0.08 vs $0.05, sales $66.9M vs $64.4M. Profitable, no offering. Spiked to $3.14, flushed to $2.76, bought back on ~7x volume. 30-min KST back over zero. Needs $3.02, then $3.19. Support $2.80, then $2.67. #VFF #cannabis #smallcaps #earnings
1
176
$TRLV in at $10.80 🌿 DEA registrations for its medical dispensaries today + 30-min KST crossed back above zero on real volume (~16x normal at 9:35). Needs to clear $10.94–$11.15, then $11.65. Support $10.47. Earnings Thursday. NFA #TRLV #MSOS #cannabis #stocks #trading
1
1
520
$TRLV update: in at $10.80, now $11.92 (+10%) 🌿 ✅ Cleared $10.94–$11.15 ✅ Broke the $11.65 Oct high KST strongest since Sept. In the $11.76–12.05 supply zone. Next $12.28–12.40, then $12.90. $11.65 = new support. Trim half ~$12.40. Earnings Thu. NFA #TRLV #cannabis
1
97
$III in at $6.20 📈 Q3 earnings: AI revenue topped $30M for the first time. Flushed to $5.42 at the open, then fully bought back. 30-min KST crossed back above zero on ~3x volume. Watching $6.30 breakout. Support $6.00. #III #smallcaps #stocks #daytrading #earnings
80
$ATWT still one of the cleaner OTC setups I’m watching. Park-Aid closed, new CEO in place, share count held steady in Q1, and chart looks interesting if .0027 support holds. Needs follow-through above .0034. NFA
1
4
323
Quick $LBRG read: tight float, AI/manufacturing story, and KST curling after a long base. Still high-risk OTC with preferred structure + restructuring history. Watching .0058-.0062 and .007+ for confirmation. NFA
162
People still talk about safemoon dam. Its been 5yrs since I spoke about safemoon.
#SafeMoon is officially down 99.9% What is next for this token?
1
1
273
Think of it like pizza. We had a small pizza, and now we're cutting it into more slices ($BLEG dilution). But those new slices are how we bought a much, much bigger pizza with better toppings! Your smaller piece is now part of a giant, amazing pizza. 🍕🙂
1
1
112
Imagine $BLEG was a messy toy box. Now, a new grown up came with a special LEGO set! We gave away some toy coupons to get it, but this LEGO set can build a whole city! Don't listen to the kids who are still playing with the old, broken toys. 🚀
2
1
3
365
The dilution authorized billions of shares to acquire a company with a patented device & a team projecting $40M in revenue At a P/S of just 1 that's a $40M market cap. Comparing that value to a $0002 price is missing the point. Dilution is the cost of a transformative deal $BLEG
2
2
4
283
To all the $BLEG haters out there asking if I have a PhD... 🎓 well, our new leadership does! And they're bringing some serious addiction therapeutics expertise (plus a $40M revenue vision). This ain't your grandpa's team. #BLEG #PhDpower
2
1
2
239
The intrinsic value of $BLEG post-merger hinges on commercializing its patented intranasal drug delivery. If the $40M revenue target is met, a 2x P/S multiple (still modest for biotech) could elevate market cap to $80M, translating to a share price of ~$0.042.
2
1
214
A successful $BLEG merger, achieving its projected $40M first-year revenue, could fundamentally re-rate its valuation. At a conservative 1x Price-to-Sales multiple, this implies a $40M market cap, driving shares to ~$0.021 from current ~$0.0008(based on ~1.9B implied shares).
1
114
The core technology acquired by $BLEG demonstrates superior absorption kinetics: 7x higher absorption in 4 mins & 4x higher in 10 mins vs. solution-based drugs in clinical studies. This PBI platform is a key differentiator. #Biopharma #Intranasal #DrugDevelopment
103
$BLEG's merger targets the burgeoning Naloxone market, valued at $1.07B in 2023 and projected to reach $2.48B by 2032. Their patented all-in-one intranasal device aims for cost reduction & enhanced precision. #Naloxone #DrugDelivery #OpioidCrisis
73
The addiction therapeutics market, targeted by $BLEG's merger, is projected to grow from $9B in 2023 to $16.7B by 2033, demonstrating a 6.6% CAGR. This significant market expansion underpins the combined entity's growth strategy. #Healthcare #MarketAnalysis #CAGR
62